Key facts
- It has raised $2.5M; the latest was Angel (individual) in Feb 2026.
- Notable investors include Kinled Holding, Austria Wirtschaftsservice, Wellcome Trust, ARAX Capital Partners, Baobá — 10 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for Eveliqure Biotechnologies
- ·The full record, as it builds
Funding rounds
No funding rounds for Eveliqure Biotechnologies are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Eveliqure Biotechnologies
Developer of a combined vaccine designed to protect against Shigella as well as against ETEC bacteria. The company's vaccine prevents diarrheal diseases and is based on a live attenuated vaccine strain of the bacterium, engineered to induce broad protection against infection caused by different species and serotypes of this pathogen, helping the healthcare industry to provide vaccines to populations at risk of diarrheal diseases.
- Sector
- Healthcare
- HQ
- Vienna, Austria
- Founded
- 2012
- Employees
- 6
- Website
- eveliqure.com/
- Ownership
- Privately Held (backing)
Eveliqure Biotechnologies doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Eveliqure Biotechnologies shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Eveliqure Biotechnologies in its N-PORT filings yet. We sweep new filings monthly.